


PHARMACEUTICAL 2017

Ocera Therapeutics Inc. Rank 226 of 313





PHARMACEUTICAL 2017

Ocera Therapeutics Inc. Rank 226 of 313

The relative strengths and weaknesses of Ocera Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ocera Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 93% points. The greatest weakness of Ocera Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 198% points.

The company's Economic Capital Ratio, given in the ranking table, is -422%, being 5.5% points below the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	28,944
Cost of Goods Sold	0
Intangible Assets	595
Liabilities, Current	13,757
Liabilities, Non-Current	0
Other Assets	36
Other Compr. Net Income	5.0
Other Expenses	0
Other Liabilities	145
Other Net Income	-1,015
Property and Equipment	64
Research and Development	16,125
Revenues	609
Selling, General and Administrative Expense	10,364

Output Variable	Value in 1000 USD
Assets	29,639
Liabilities	13,902
Expenses	26,489
Stockholders Equity	15,737
Net Income	-26,895
Comprehensive Net Income	-26,892
Economic Capital Ratio	-422%